Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (98)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (5)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (297)
  2. Department of Medicine (297)
  3. Hematologic Malignancies, Division of (297)
  4. Myeloma (297)
  5. Survivorship Research (216)
  6. Hematologic Malignancies Research (212)

More Groups

People
  1. Neha Korde (191)
  2. Alexander Lesokhin (170)
  3. Hani Hassoun (163)
  4. Sergio Giralt (161)
  5. Malin Hultcrantz (158)
  6. Heather Landau (147)

More People

Years
  1. 2025 (13)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (96)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. Blood Cancer Journal (12)
  5. JAMA Oncology (12)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (107)
  2. Elsevier Inc. (71)
  3. Nature Publishing Group (26)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Early experience with salvage RT for relapsed / refractory multiple myeloma following BCMA-directed CART cell therapy
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Mailankody, S.; Usmani, S.; Imber, B. S.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Failure patterns by PET for relapsed / refractory Multiple Myeloma (r/r MM) after CART cell therapy: Potential role for radiotherapy (RT)?
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Hubbeling, H. G.; Mailankody, S.; Usmani, S.; Yahalom, J.; Imber, B. S.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of BMS-986393 in patients with quadruple-class exposed relapsed or refractory multiple myeloma
    Meeting Abstract

    Patel, K.; Nadeem, O.; Munshi, N.; Iida, S.; Mailankody, S.; Neri, P.; Gregory, T.; Piasecki, J.; Ziyad, S.; Hu, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save